Table 3.

Multivariate Analyses of Prognostic Factors

Prognostic Factor	Survival
	PFS			OS
	Hazard Ratio*	95% CI	P	Hazard Ratio*	95% CI	P
Model including treatment as a variable (n = 80)†
Received rituximab-based therapy†	0.23	0.10 to 0.55	.0009	0.21	0.08 to 0.53	.0009
CNS involvement	5.66	1.61 to 19.97	.007	3.88	1.09 to 13.86	.04
> 1 extranodal site	2.59	1.07 to 6.28	.04	2.14	0.87 to 5.31	.10
Hypoalbuminemia	2.67	0.86 to 8.26	.09	3.93	1.10 to 14.07	.04
Model P	< .0001			< .0001
Model excluding treatment as a variable (n = 80)
CNS involvement	4.70	1.45 to 15.20	.0099	3.61	1.06 to 12.32	.04
Bone marrow involvement	2.95	1.13 to 7.68	.03	3.14	1.14 to 8.65	.03
Hypoalbuminemia	2.96	1.01 to 8.98	.055	3.64	1.05 to 12.60	.04
Model P	.0004			.0003

Abbreviations: PFS, progression-free survival; OS, overall survival.

^*Hazard ratios > 1 indicate a factor with poor prognosis, whereas those < 1 indicate a factor with favorable prognosis.

^†Treatment: rituximab-based therapy as a part of first-line post-transplantation lymphoproliferative disease therapy v not as part of first-line therapy.